Achieve Life Sciences, Inc. - Common Shares (ACHV)
4.7500
+0.3100 (6.98%)
NASDAQ · Last Trade: Dec 30th, 1:48 PM EST
Detailed Quote
Previous Close
4.440
Open
4.450
Bid
4.730
Ask
4.760
Day's Range
4.300 - 4.950
52 Week Range
1.840 - 5.780
Volume
1,957,961
Market Cap
85.69M
PE Ratio (TTM)
-3.442
EPS (TTM)
-1.4
Dividend & Yield
N/A (N/A)
1 Month Average Volume
494,397
Chart
About Achieve Life Sciences, Inc. - Common Shares (ACHV)
Achieve Life Sciences is a biopharmaceutical company focused on developing innovative treatments for nicotine addiction and smoking cessation. The company is advancing its proprietary therapies aimed at addressing the global health challenge of tobacco dependence, utilizing both pharmacological and non-pharmacological approaches. Through rigorous research and clinical trials, Achieve Life Sciences strives to improve patient outcomes and support public health initiatives aimed at reducing the prevalence of smoking and its associated health risks. Their commitment to innovation and patient-centered solutions positions them at the forefront of the fight against nicotine addiction. Read More
In a move that has sent ripples through the biotech sector on the final trading days of the year, Hunterbrook Capital announced a significant bullish position in Achieve Life Sciences (NASDAQ:ACHV) today, December 30, 2025. The investment firm, which operates a unique hybrid model of investigative journalism and hedge
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
HC Wainwright backs Achieve Life Sciences with a Buy rating as cytisinicline nears potential 2026 FDA approval, targeting a large smoking cessation market.
Achieve Life Sciences reports Q2 2025 results with $0.0 revenue and -$0.37 EPS, meeting estimates. Shares rise 2.3% pre-market as focus remains on cytisinicline development for smoking cessation.
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
